Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
18°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aura Biosciences Inc
(NQ:
AURA
)
9.030
+0.280 (+3.20%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aura Biosciences Inc
< Previous
1
2
3
4
Next >
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
October 18, 2024
Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety profile.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 14, 2024
Via
Benzinga
3 Small-Cap Stocks Ready to Deliver Significant Growth
October 10, 2024
Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Recap: Aura Biosciences Q4 Earnings
March 27, 2024
Via
Benzinga
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
September 12, 2024
Aura Biosciences announced promising Phase 2 results for bel-sar in treating melanoma, achieving 80% tumor control.
Via
Benzinga
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024
August 08, 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
May 09, 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023
March 27, 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 27, 2024
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
February 26, 2024
From
Aura Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 09, 2024
Via
Benzinga
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
December 07, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
November 10, 2023
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
November 09, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
November 08, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Why Aura Biosciences Stock Hit A New 52-Week Low Today
November 07, 2023
Aura Biosciences Inc (NASDAQ: AURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common st
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 07, 2023
Via
Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 07, 2023
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Via
Benzinga
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
November 07, 2023
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 07, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 07, 2023
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.
Via
InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 07, 2023
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
November 06, 2023
Via
Benzinga
Aura Biosciences Announces Proposed Public Offering of Common Stock
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
November 06, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Fall Off A Cliff This Month
November 06, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
October 31, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
October 02, 2023
From
Aura Biosciences Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.